Contact this trialFirst, we need to learn more about you.
LAM-001 for Bronchiolitis Obliterans Syndrome
Recruiting0 awardsPhase 2
San Francisco, California
This trial will investigate the safety and effectiveness of inhaled sirolimus to slow bronchiolitis obliterans syndrome (BOS) progression in lung transplant recipients. Participants will be randomly assigned to inhale sirolimus or placebo for 48 weeks and attend 10 visits.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service